HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA In Brief

This article was originally published in The Rose Sheet

Executive Summary

OTC drug labeling: FDA's toll-free MedWatch number will be required on all non-monograph OTC drug products, effective April 22, 2005, agency announces. Published April 22 in the Federal Register, the proposal recommends the statement be placed in the "Warnings" section of the Drug Facts panel, under the "Stop Use and Ask a Doctor If" subheading. FDA is recommending that the side effects statement first direct consumers to consult a doctor for medical advice if side effects occur. The labeling addition is required under Best Pharmaceuticals for Children Act, which became law in 2002. The agency estimates 522 OTCs will be subject to the rule, and predicts OTC drug manufacturers will incur a one-time cost of $1.2 mil.-$3.7 mil., depending upon the number of affected SKUs...

You may also be interested in...



Skin Protectant Final Rule Allows Cross-Monograph Ingredient Combinations

The Skin Protectant Final Monograph covering products for minor cuts, scrapes, burns, chapped skin and lips, poison ivy, poison oak, poison sumac and insect bites allows for certain cross-monograph ingredient combinations, according to the rule published in the 1Federal Register June 4

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
UsernamePublicRestriction

Register

RS012074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel